(Post-pandemic Era)-Global Biobanking Sample Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Report Code : XYZ2438543
- Published On: Apr, 2021
- Category : Medical Devices
- Pages : 112
-
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Research published a report for global Biobanking Sample market in this environment.
In terms of revenue, this research report indicated that the global Biobanking Sample market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Biobanking Sample industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Thermo Fisher Scientific Inc. (U.S.) aims at producing XX K Units Biobanking Sample in 2020, with XX % production to take place in global market, Tecan Group Ltd. (Switzerland) accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Biobanking Sample Market Include by
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Biobanking Sample Market
Thermo Fisher Scientific Inc. (U.S.)
Tecan Group Ltd. (Switzerland)
Qiagen N.V. (Germany)
Hamilton Company (U.S.)
Brooks Automation (U.S.)
TTP Labtech Ltd (U.K.)
VWR Corporation (U.S.)
Promega Corporation (U.S.)
Worthington Industries [(Taylor Wharton, U.S.)]
Chart Industries (U.S.)
Becton, Dickinson and Company (U.S.)
Merck KGaA (Germany)
Micronic (Netherlands)
LVL Technologies GmbH & Co. KG (Germany)
Panasonic Healthcare Holdings Co. Ltd (Japan)
Greiner Bio One [Greiner Holding AG, Austria)]
Biokryo GmbH (Germany)
Major Type of Biobanking Sample Covered in Research report:
Blood Products
Human Tissues
Nucleic Acids
Cell Lines
Biological Fluids
Human Waste Products
Application Segments Covered in Research Market
Regenerative Medicine
Life Science Research
Clinical Research
For any other requirements, please feel free to contact us and we will provide you customized report.
-
With tables and figures helping analyze worldwide (Post pandemic Era) Global Biobanking Sample market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Global Biobanking Sample Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope1.1 Product Details and Introduction
1.1.1 Blood Products -Product Introduction and Major Manufacturers
1.1.2 Human Tissues -Product Introduction and Major Manufacturers
1.1.3 Nucleic Acids -Product Introduction and Major Manufacturers
1.1.4 Cell Lines -Product Introduction and Major Manufacturers
1.1.5 Biological Fluids -Product Introduction and Major Manufacturers
1.1.6 Human Waste Products -Product Introduction and Major Manufacturers1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Biobanking Sample Market Assessment, by Segmentation2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis3.1 China Biobanking Sample Market
3.1.1 Top Companies leading Biobanking Sample Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Biobanking Sample Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)3.2 EU Biobanking Sample Market
3.2.1 Top Companies leading Biobanking Sample Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Biobanking Sample Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)3.3 USA Biobanking Sample Market
3.3.1 Top Companies leading Biobanking Sample Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Biobanking Sample Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)3.4 Japan Biobanking Sample Market
3.4.1 Top Companies leading Biobanking Sample Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Biobanking Sample Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)3.5 India Biobanking Sample Market
3.5.1 Top Companies leading Biobanking Sample Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Biobanking Sample Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)3.6 Southeast Asia Biobanking Sample Market
3.6.1 Top Companies leading Biobanking Sample Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Biobanking Sample Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Biobanking Sample Market
3.7.1 Top Companies leading Biobanking Sample Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Biobanking Sample Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)4.1 Biobanking Sample Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream4.2 COVID-19 Impact on Biobanking Sample Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)5.1 Global Biobanking Sample Sales and Growth Rate (2021-2027)
5.2 Global Biobanking Sample Sales Value and Growth Rate (2021-2027)
6 Biobanking Sample Competitive Analysis6.1 Thermo Fisher Scientific Inc. (U.S.)
6.1.1 Thermo Fisher Scientific Inc. (U.S.) Company Profiles
6.1.2 Thermo Fisher Scientific Inc. (U.S.) Product Introduction
6.1.3 Thermo Fisher Scientific Inc. (U.S.) Biobanking Sample Production, Revenue (2016-2021)
6.1.4 SWOT Analysis6.2 Tecan Group Ltd. (Switzerland)
6.2.1 Tecan Group Ltd. (Switzerland) Company Profiles
6.2.2 Tecan Group Ltd. (Switzerland) Product Introduction
6.2.3 Tecan Group Ltd. (Switzerland) Biobanking Sample Production, Revenue (2016-2021)
6.2.4 SWOT Analysis6.3 Qiagen N.V. (Germany)
6.3.1 Qiagen N.V. (Germany) Company Profiles
6.3.2 Qiagen N.V. (Germany) Product Introduction
6.3.3 Qiagen N.V. (Germany) Biobanking Sample Production, Revenue (2016-2021)
6.3.4 SWOT Analysis6.4 Hamilton Company (U.S.)
6.4.1 Hamilton Company (U.S.) Company Profiles
6.4.2 Hamilton Company (U.S.) Product Introduction
6.4.3 Hamilton Company (U.S.) Biobanking Sample Production, Revenue (2016-2021)
6.4.4 SWOT Analysis6.5 Brooks Automation (U.S.)
6.5.1 Brooks Automation (U.S.) Company Profiles
6.5.2 Brooks Automation (U.S.) Product Introduction
6.5.3 Brooks Automation (U.S.) Biobanking Sample Production, Revenue (2016-2021)
6.5.4 SWOT Analysis6.6 TTP Labtech Ltd (U.K.)
6.6.1 TTP Labtech Ltd (U.K.) Company Profiles
6.6.2 TTP Labtech Ltd (U.K.) Product Introduction
6.6.3 TTP Labtech Ltd (U.K.) Biobanking Sample Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 VWR Corporation (U.S.)
6.7.1 VWR Corporation (U.S.) Company Profiles
6.7.2 VWR Corporation (U.S.) Product Introduction
6.7.3 VWR Corporation (U.S.) Biobanking Sample Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Promega Corporation (U.S.)
6.8.1 Promega Corporation (U.S.) Company Profiles
6.8.2 Promega Corporation (U.S.) Product Introduction
6.8.3 Promega Corporation (U.S.) Biobanking Sample Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 Worthington Industries [(Taylor Wharton, U.S.)]
6.9.1 Worthington Industries [(Taylor Wharton, U.S.)] Company Profiles
6.9.2 Worthington Industries [(Taylor Wharton, U.S.)] Product Introduction
6.9.3 Worthington Industries [(Taylor Wharton, U.S.)] Biobanking Sample Production, Revenue (2016-2021)
6.9.4 SWOT Analysis6.10 Chart Industries (U.S.)
6.10.1 Chart Industries (U.S.) Company Profiles
6.10.2 Chart Industries (U.S.) Product Introduction
6.10.3 Chart Industries (U.S.) Biobanking Sample Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 Becton, Dickinson and Company (U.S.)
6.12 Merck KGaA (Germany)
6.13 Micronic (Netherlands)
6.14 LVL Technologies GmbH & Co. KG (Germany)
6.15 Panasonic Healthcare Holdings Co. Ltd (Japan)
6.16 Greiner Bio One [Greiner Holding AG, Austria)]
6.17 Biokryo GmbH (Germany)
7 Conclusion
-
The (Post pandemic Era) Global Biobanking Sample Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players:
By Regions:
By Type:
By Application:
Frequently asked questions(FAQ's):
New players are entering the (Post pandemic Era) Global Biobanking Sample Market, while established companies are changing their business models and strategies. This pattern is likely to continue for the foreseeable future.
Depending upon the type of applications, the (Post pandemic Era) Global Biobanking Sample Market has been segmented into
The (Post pandemic Era) Global Biobanking Sample Market is expected to grow at a moderate CAGR during the forecast period of 2024 to 2029.
Consumer behavior changes will reshape the entire decision-making process and companies in the (Post pandemic Era) Global Biobanking Sample Industry will need to adapt quickly.
The (Post pandemic Era) Global Biobanking Sample study focuses on shifting market dynamics, geopolitical and regulatory regulations, and key players' strategies to carefully analyze demand at risk across multiple industry categories.
